Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates
Authors:
- Caroline Rodrigues Chaves dos ReisCRCaroline Rodrigues Chaves dos Reis
- Hellen Valério Chaves Moura de SouzaHSHellen Valério Chaves Moura de Souza
- Lidia Corrêa ParraLPLidia Corrêa Parra
- Guilber Valério Chaves Moura de SouzaGSGuilber Valério Chaves Moura de Souza
- Bruna Costa ZorzanelliBZBruna Costa Zorzanelli
- Nubia BoechatNBNubia Boechat
- Lucas Villas Bôas HoelzLHLucas Villas Bôas Hoelz
- Tácio Vinício Amorim FernandesTFTácio Vinício Amorim Fernandes
Open Access
- 14 June 2026
- journal article
- review article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (6) , e70340
Abstract
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (447623/2024‐9)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (440006/2022‐8)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ‐JCNE E‐26/201.268/2021)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001)
This publication has 63 references indexed in Scilit:
- Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas’ diseaseBioorganic & Medicinal Chemistry Letters, 2006
- Human and Parasitic Papain-Like Cysteine Proteases: Their Role in Physiology and Pathology and Recent Developments in Inhibitor DesignChemical Reviews, 2002
- Synthesis and Structure−Activity Relationship Study of Potent Trypanocidal Thio Semicarbazone Inhibitors of the Trypanosomal Cysteine Protease CruzainJournal of Medicinal Chemistry, 2002
- Cysteine proteases of parasitic organismsMolecular and Biochemical Parasitology, 2002
- Analysis of the S2 subsite specificities of the recombinant cysteine proteinases CPB of Leishmania mexicana, and cruzain of Trypanosoma cruzi, using fluorescent substrates containing non-natural basic amino acidsMolecular and Biochemical Parasitology, 2001
- The Major Cysteine Proteinase of Trypanosoma cruzi: A Valid Target for Chemotherapy of Chagas DiseaseCurrent Pharmaceutical Design, 2001
- Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi InfectionJournal of Experimental Medicine, 1998
- Structural determinants of specificity in the cysteine protease cruzainProtein Science, 1997
- The Crystal Structure of Cruzain: A Therapeutic Target for Chagas' DiseaseJournal of Molecular Biology, 1995
- The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi.Journal of Biological Chemistry, 1992